BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (LAPIX), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (œLAPIX), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc., a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune...
LAPIX Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA